ZA200408111B - Treatment of gastroparesis. - Google Patents

Treatment of gastroparesis.

Info

Publication number
ZA200408111B
ZA200408111B ZA200408111A ZA200408111A ZA200408111B ZA 200408111 B ZA200408111 B ZA 200408111B ZA 200408111 A ZA200408111 A ZA 200408111A ZA 200408111 A ZA200408111 A ZA 200408111A ZA 200408111 B ZA200408111 B ZA 200408111B
Authority
ZA
South Africa
Prior art keywords
gastroparesis
treatment
Prior art date
Application number
ZA200408111A
Other languages
English (en)
Inventor
Joseph Anthony Jakubowski
Thurman Dwight Mckinney
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA200408111B publication Critical patent/ZA200408111B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ZA200408111A 2002-04-10 2004-10-07 Treatment of gastroparesis. ZA200408111B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37165002P 2002-04-10 2002-04-10

Publications (1)

Publication Number Publication Date
ZA200408111B true ZA200408111B (en) 2005-10-07

Family

ID=29250714

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200408111A ZA200408111B (en) 2002-04-10 2004-10-07 Treatment of gastroparesis.

Country Status (18)

Country Link
US (1) US20050164925A1 (enExample)
EP (1) EP1496924A4 (enExample)
JP (1) JP2005530732A (enExample)
KR (1) KR20040098063A (enExample)
CN (1) CN1735423A (enExample)
AU (1) AU2003220403A1 (enExample)
BR (1) BR0308904A (enExample)
CA (1) CA2480858A1 (enExample)
EA (1) EA200401345A1 (enExample)
EC (1) ECSP045345A (enExample)
HR (1) HRP20040939A2 (enExample)
IL (1) IL164266A0 (enExample)
MX (1) MXPA04009929A (enExample)
NO (1) NO20044815L (enExample)
NZ (1) NZ535684A (enExample)
PL (1) PL373658A1 (enExample)
WO (1) WO2003087139A2 (enExample)
ZA (1) ZA200408111B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
EP1670515A2 (en) * 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
WO2006018851A2 (en) 2004-08-18 2006-02-23 Metacure Ltd. Monitoring, analysis, and regulation of eating habits
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
EP1880298B1 (en) 2005-02-17 2016-07-13 Metacure Limited Charger with data transfer capabilities
JP5755398B2 (ja) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス 伸長されたｇｌｐ−１化合物
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
ATE533403T1 (de) * 2005-03-24 2011-12-15 Metacure Ltd Drahtlose leitungen für magen-darm-trakt- anwendungen
WO2007080595A2 (en) 2006-01-12 2007-07-19 Metacure N.V. Electrode assemblies, tools, and methods for gastric wall implantation
US8301256B2 (en) 2005-06-02 2012-10-30 Metacure Limited GI lead implantation
US8442841B2 (en) * 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
JP2009534423A (ja) * 2006-04-20 2009-09-24 アムジェン インコーポレイテッド Ｇｌｐ−１化合物
AU2012203915B9 (en) * 2006-04-20 2014-10-09 Amgen Inc. GLP-1 compounds
WO2008139463A2 (en) * 2007-05-09 2008-11-20 Metacure Ltd. Analysis and regulation of food intake
US8423130B2 (en) * 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
AU2009279090A1 (en) 2008-08-06 2010-02-11 Novo Nordisk Health Care Ag Conjugated proteins with prolonged in vivo efficacy
KR20110122100A (ko) 2009-01-22 2011-11-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 안정한 성장 호르몬 화합물
CN102612376A (zh) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
WO2011017554A2 (en) * 2009-08-07 2011-02-10 Mannkind Corporation Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
MX345736B (es) 2010-01-22 2017-02-14 Novo Nordisk Healthcare Ag Hormonas de crecimiento con eficacia in vivo prolongada.
EP2525833A2 (en) 2010-01-22 2012-11-28 Novo Nordisk Health Care AG Stable growth hormone compounds
WO2011092710A2 (en) * 2010-02-01 2011-08-04 Metacure Limited Gastrointestinal electrical therapy
CA2793715A1 (en) 2010-04-30 2011-11-03 Sanwa Kagaku Kenkyusho Co., Ltd. Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP6408998B2 (ja) 2012-12-21 2018-10-17 サノフイＳａｎｏｆｉ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニスト
ES2841123T3 (es) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Formulación del compuesto de la hormona de crecimiento

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP2002510193A (ja) * 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド−１類似体
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Also Published As

Publication number Publication date
WO2003087139A2 (en) 2003-10-23
HRP20040939A2 (en) 2004-12-31
JP2005530732A (ja) 2005-10-13
CN1735423A (zh) 2006-02-15
KR20040098063A (ko) 2004-11-18
IL164266A0 (en) 2005-12-18
WO2003087139A3 (en) 2004-01-08
NO20044815L (no) 2005-01-07
NZ535684A (en) 2006-03-31
EP1496924A2 (en) 2005-01-19
AU2003220403A1 (en) 2003-10-27
US20050164925A1 (en) 2005-07-28
EA200401345A1 (ru) 2005-08-25
CA2480858A1 (en) 2003-10-23
MXPA04009929A (es) 2006-03-10
PL373658A1 (en) 2005-09-05
ECSP045345A (es) 2006-04-19
EP1496924A4 (en) 2007-05-30
BR0308904A (pt) 2005-05-03

Similar Documents

Publication Publication Date Title
ZA200408111B (en) Treatment of gastroparesis.
IL218909A0 (en) Treatment of diabetes
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
GB0112343D0 (en) Well treatment
GB0201674D0 (en) Medical treatment
GB0223367D0 (en) Therapeutic treatment
GB0218879D0 (en) Medical treatment
GB0213869D0 (en) The treatment of pain
GB2388557B (en) Treatment system
GB0223854D0 (en) Therapeutic treatment
GB0210464D0 (en) Therapeutic treatment
GB0221157D0 (en) Novel treatment
GB0217493D0 (en) Novel methods of treatment
GB0223650D0 (en) Psoriasis treatment
GB0221712D0 (en) Methods of treatment
AU2003292367A8 (en) Soil treatment
GB0213198D0 (en) Method of treatment
GB0211297D0 (en) Pain treatment
AP2004002980A0 (en) The treatment of lipodystrophy.
HK1074388A (en) Treatment of gastroparesis
GB0207091D0 (en) Method of treatment
GB0213493D0 (en) Treatment
GB0220820D0 (en) Treatment
GB0218818D0 (en) Novel treatment